To evaluate the safety and efficacy of stenting for symptomatic intracranial atherosclerotic severe stenosis or occlusion with Enterprise stents.
Methods
Fifty-three consecutive patients with symptomatic intracranial atherosclerotic severe (70%–99%) stenosis or occlusion who underwent endovascular treatment with Enterprise stents between September 2019 and March 2022 were retrospectively analyzed. Primary outcomes included technical stenting success rates, the incidence of complications within 30 days of the procedure, and the in-stent restenosis rates during the follow-up period. These outcomes were further categorized based on lesion location and operation time.
Results
Fifty-seven lesions in 53 patients aged 61.0 ± 10.0 years were treated with Enterprise stents with a technical success rate of 100%. Seven patients (12.3%) had severe complications within 30 days of the procedure: five had a symptomatic ischemic stroke, one had a symptomatic intracerebral hemorrhage, and one had a subarachnoid hemorrhage related to the procedure. No deaths were observed. The rate of in-stent restenosis was 18.2%, with a mean vascular imaging follow-up period of 6.7 months. The 30-day complication and in-stent restenosis rates did not differ significantly between patients with different lesion locations and operation times (P > 0.05).
Conclusion
This retrospective study suggests that percutaneous transluminal angioplasty and stenting with Enterprise stents is an effective treatment for symptomatic intracranial arterial stenosis or occlusion with a high technical success rate. It also indicates that stenting during the early nonacute stage after stroke may not increase the incidence of perioperative complications for symptomatic intracranial atherosclerotic stenosis when following strict inclusion criteria.
SaccoRLKargmanDEGuQ,et al.Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke1995; 26: 14–20.
2.
WitykRJLehmanDKlagM,et al.Race and sex differences in the distribution of cerebral atherosclerosis. Stroke1996; 27: 1974–1980.
3.
CaplanLRGorelickPBHierDB. Race, sex and occlusive cerebrovascular disease: a review. Stroke1986; 17: 648–655.
4.
PuYLiuLWangY, et al.Geographic and sex difference in the distribution of intracranial atherosclerosis in China. Stroke2013; 44: 2109–2114.
5.
ChimowitzMILynnMJDerdeynCP, et al.Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med2011; 365: 993–1003.
6.
ZaidatOOFitzsimmonsBFWoodwardBK, et al.Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA2015; 313: 1240–1248.
7.
ChimowitzMILynnMJHowlett-SmithH, et al.Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med2005; 352: 1305–1316.
8.
MiaoZZhangYShuaiJ, et al.Thirty-day outcome of a multicenter registry study of stenting for symptomatic intracranial artery stenosis in China. Stroke2015; 46: 2822–2829.
9.
GaoPWangDZhaoZ, et al.Multicenter prospective trial of stent placement in patients with symptomatic high-grade intracranial stenosis. AJNR Am J Neuroradiol2016; 37: 1275–1280.
10.
MaierILKarchALipkeC, et al.Transluminal angioplasty and stenting versus conservative treatment in patients with symptomatic basilar artery stenosis : perspective for future clinical trials. Clin Neuroradiol2018; 28: 33–38.
11.
AlexanderMJZaunerAChaloupkaJC, et al.WEAVE trial: final results in 152 on-label patients. Stroke2019; 50: 889–894.
FengXQianZLiuP, et al.Comparison of recanalization and in-stent stenosis between the low-profile visualized intraluminal support stent and Enterprise stent-assisted coiling for 254 intracranial aneurysms. World Neurosurg2018; 109: e99–e104.
14.
LimbucciNRenieriLNappiniS,et al.Y-stent assisted coiling of bifurcation aneurysms with Enterprise stent: long-term follow-up. J Neurointerv Surg2016; 8: 158–162.
15.
WeberWBendszusMKisB,et al.A new self-expanding nitinol stent (Enterprise) for the treatment of wide-necked intracranial aneurysms: initial clinical and angiographic results in 31 aneurysms. Neuroradiology2007; 49: 555–561.
16.
SunBXuCWuP, et al.Intracranial angioplasty with Enterprise stent for intracranial atherosclerotic stenosis: a single-center experience and a systematic review. Biomed Res Int2021; 2021: 6645500.
17.
JungWSKimSSLeeKY,et al.Usefulness of self-expandable stent for recanalization of intracranial atherosclerotic disease: preliminary experience with Enterprise stent. Neurointervention2022; 17: 37–44.
18.
FengZDuanGZhangP, et al.Enterprise stent for the treatment of symptomatic intracranial atherosclerotic stenosis: an initial experience of 44 patients. BMC Neurol2015; 15: 187.
19.
ZhangLHuangQZhangY, et al.Wingspan stents for the treatment of symptomatic atherosclerotic stenosis in small intracranial vessels: safety and efficacy evaluation. AJNR Am J Neuroradiol2012; 33: 343–347.
20.
SalikAESelcukHHZalovH,et al.Medium-term results of undersized angioplasty and stenting for symptomatic high-grade intracranial atherosclerotic stenosis with Enterprise. Interv Neuroradiol2019; 25: 484–490.
21.
HuangCMHongYFXingSH, et al.Thirty-day outcomes of the Enterprise stent in treating hypoperfusion of symptomatic intracranial stenosis. World Neurosurg2019; 129: e429–e435.
22.
WabnitzAChimowitzM. Angioplasty, stenting and other potential treatments of atherosclerotic stenosis of the intracranial arteries: past, present and future. J Stroke2017; 19: 271–276.
23.
DerdeynCPChimowitzMILynnMJ, et al.Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet2014; 383: 333–341.
24.
TuranTNZaidatOOGronsethGS, et al.Stroke prevention in symptomatic large artery intracranial atherosclerosis practice advisory: report of the AAN guideline subcommittee. Neurology2022; 98: 486–498.
25.
HussainMDattaNChengZ, et al.Spanning from the West to East: an updated review on endovascular treatment of intracranial atherosclerotic disease. Aging Dis2017; 8: 196–202.
26.
LeeKYChenDYHsuHL,et al.Undersized angioplasty and stenting of symptomatic intracranial tight stenosis with Enterprise: evaluation of clinical and vascular outcome. Interv Neuroradiol2016; 22: 187–195.
27.
GaoPWangTWangD, et al.Effect of stenting plus medical therapy vs medical therapy alone on risk of stroke and death in patients with symptomatic intracranial stenosis: the CASSISS randomized clinical trial. JAMA2022; 328: 534–542.
28.
LevyEITurkASAlbuquerqueFC, et al.Wingspan in-stent restenosis and thrombosis: incidence, clinical presentation, and management. Neurosurgery2007; 61: 644–650; discussion 650–1.
29.
JinMFuXWeiY,et al.Higher risk of recurrent ischemic events in patients with intracranial in-stent restenosis. Stroke2013; 44: 2990–2994.
30.
PengGZhangYMiaoZ. Incidence and risk factors of in-stent restenosis for symptomatic intracranial atherosclerotic stenosis: a systematic review and meta-analysis. AJNR Am J Neuroradiol2020; 41: 1447–1452.
31.
KrischekOMiloslavskiEFischerS,et al.A comparison of functional and physical properties of self-expanding intracranial stents [Neuroform3, Wingspan, Solitaire, Leo+, Enterprise]. Minim Invasive Neurosurg2011; 54: 21–28.
32.
ChenKHouXZhouZ, et al.The efficacy and safety of endovascular recanalization of occluded large cerebral arteries during the subacute phase of cerebral infarction: a case series report. Stroke Vasc Neurol2017; 2: 124–131.
33.
GaoBSafainMGMalekAM. Enterprise stenting for intracranial aneurysm treatment induces dynamic and reversible age-dependent stenosis in cerebral arteries. J Neurointerv Surg2015; 7: 297–302.
34.
KimYSLeeSWYeomJA,et al.Angiographic findings of in-stent intimal hyperplasia after stent-assisted coil embolization: are they permanent findings. J Neurosurg2016; 124: 328–333.
35.
ZhangKLiTXWangZL, et al.Factors affecting in-stent restenosis after angioplasty with the Enterprise stent for intracranial atherosclerotic diseases. Sci Rep2021; 11: 10479.
36.
GuptaRSchumacherHCManglaS, et al.Urgent endovascular revascularization for symptomatic intracranial atherosclerotic stenosis. Neurology2003; 61: 1729–1735.
37.
MarksMPWojakJCAl-AliF, et al.Angioplasty for symptomatic intracranial stenosis: clinical outcome. Stroke2006; 37: 1016–1020.
38.
WangTYangKZhangX, et al.Endovascular therapy for symptomatic intracranial artery stenosis: a systematic review and network meta-analysis. Transl Stroke Res2022; 13: 676–685.
39.
AbdollahifardSYousefiOKamranH,et al.Balloon-mounting stent for intracranial arterial stenosis: a comprehensive and comparative systematic review and meta-analysis. Interv Neuroradiol2022: 15910199221100620.
40.
AlexanderMJZaunerAGuptaR, et al.The WOVEN trial: wingspan one-year vascular events and neurologic outcomes. J Neurointerv Surg2021; 13: 307–310.
41.
VajdaZSchmidEGütheT, et al.The modified Bose method for the endovascular treatment of intracranial atherosclerotic arterial stenoses using the Enterprise stent. Neurosurgery2012; 70: 91–101; discussion 101.
42.
WangXWangZWangC, et al.Application of the Enterprise stent in atherosclerotic intracranial arterial stenosis: a series of 60 cases. Turk Neurosurg2016; 26: 69–76.
